Drug discovery and development: Lessons from an undeveloped drug

Expert Review of Clinical Pharmacology

Volumn 5, Issue 2, 2012, Pages 157-162

  Gordi, Toufigh ^a  

^a Rosa and Co LLC   (United States)

Author keywords

drug development; drug discovery; pharmacodynamics; pharmacokinetics; quantitative analysis; systems pharmacology

Indexed keywords

ACETYLSALICYLIC ACID; ARTEMETHER; ARTEMISININ DERIVATIVE; BENFLUMETOL; BETA ARTEMETHER; DIHYDROARTEMISININ; MEFLOQUINE; NALOXONE; OFLOXACIN; UNCLASSIFIED DRUG;

ANTIMALARIAL ACTIVITY; ARTEMISIA ANNUA; DISEASE COURSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG INDUSTRY; DRUG MARKETING; DRUG METABOLISM; DRUG SCREENING; HUMAN; MALARIA FALCIPARUM; NONHUMAN; PHARMACODYNAMICS; QUANTITATIVE ANALYSIS; REVIEW;

ANIMALS; ANTIMALARIALS; ARTEMISININS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; MODELS, THEORETICAL; ORPHAN DRUG PRODUCTION;

EID: 84858433954     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.11.76     Document Type: Review

References (42)

1. Woodcock J, Woosley R. The FDA critical path initiative and its influence on new drug development. Ann. Rev. Med. 59, 1-12 (2008).
2. Li Y, Wu YL. How Chinese scientists discovered qinghaosu (artemisinin) and developed its derivatives? What are the future perspectives? Med. Trop. (Mars). 58, 9-12 (1998).
3. Gautam A, Ahmed T, Batra V, Paliwal J. Pharmacokinetics and pharmacodynamics of endoperoxide antimalarials. Curr. Drug Metab. 10, 289-306 (2009).
4. Davis TM, Phuong HL, Ilett KF et al. Pharmacokinetics and pharmacodynamics of intravenous artesunate in severe falciparum malaria. Antimicrob. Agents Chemother. 45, 181-186 (2001).
5. White NJ. Antimalarial drug resistance. J. Clin. Invest. 113, 1084-1092 (2004).
6. Carrara VI, Zwang J, Ashley EA et al. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS One 4, e4551 (2009).
7. Dondorp AM, Yeung S, White L et al. Artemisinin resistance: Current status and scenarios for containment. Nat. Rev. Microbiol. 8, 272-280 (2010).
8. Ashton M, Nguyen DS, Nguyen VH et al. Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria. Clin. Pharmacol. Ther. 63, 482-493 (1998).
9. Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am. J. Trop. Med. Hyg. 77, 181-192 (2007).
10. Nosten F, van Vugt M, Price R et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: A prospective study. Lancet 356, 297-302 (2000).
11. Ashton M, Hai TN, Sy ND et al. Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults. Drug Metab. Dispos. 26, 25-27 (1998).
12. Ashton M, Gordi T, Trinh NH et al. Artemisinin pharmacokinetics in healthy adults after 250, 500 and 1000 mg single oral doses. Biopharm. Drug Dispos. 19, 245-250 (1998).
13. Svensson US, Ashton M. Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br. J. Clin. Pharmacol. 48, 528-535 (1999).
14. Asimus S, Hai TN, Van Huong N, Ashton M. Artemisinin and CYP2A6 activity in healthy subjects. Eur. J. Clin. Pharmacol. 64, 283-292 (2008).
15. Bapiro TE, Sayi J, Hasler JA et al. Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans. Eur. J. Clin. Pharmacol. 61, 755-761 (2005).
16. Meshnick SR, Yang YZ, Lima V, Kuypers F, Kamchonwongpaisan S, Yuthavong Y. Iron-dependent free radical generation from the antimalarial agent artemisinin (qinghaosu). Antimicrob. Agents Chemother. 37, 1108-1114 (1993).
17. Meshnick SR. Artemisinin antimalarials: Mechanisms of action and resistance. Med. Trop. (Mars). 58, 13-17 (1998).
18. Golenser J, Waknine JH, Krugliak M, Hunt NH, Grau GE. Current perspectives on the mechanism of action of artemisinins. Int. J. Parasitol. 36, 1427-1441 (2006).
19. Price R, van Vugt M, Phaipun L et al. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am. J. Trop. Med. Hyg. 60, 547-555 (1996).
20. Wesche DL, DeCoster MA, Tortella FC, Brewer TG. Neurotoxicity of artemisinin analogs in vitro. Antimicrob. Agents Chemother. 38, 1813-1819 (1994).
21. Genovese RF, Newman DB, Brewer TG. Behavioral and neural toxicity of the artemisinin antimalarial, arteether, but not artesunate and artelinate, in rats. Pharmacol. Biochem. Behav. 67, 37-44 (2000).
22. Brewer TG, Grate SJ, Peggins JO et al. Fatal neurotoxicity of arteether and artemether. Am. J. Trop. Med. Hyg. 51, 251-259 (1994).
23. Petras JM, Young GD, Bauman RA et al. Arteether-induced brain injury in Macaca mulatta. I. The precerebellar nuclei: The lateral reticular nuclei, paramedian reticula nuclei, and perihypoglossal nuclei. Anat. Embryol. 20, 383-397 (2000).
24. Davis TM, Binh TQ, Ilett KF et al. Penetration of dihydroartemisinin into cerebrospinal fluid after administration of intravenous artesunate in severe falciparum malaria. Antimicrob. Agents Chemother. 47, 368-370 (2003).
25. White NJ. Neurological dysfunction following malaria: Disease- or drug-related? Clin. Infect. Dis. 30, 836 (2000).
26. Gordi T, Huong DX, Hai TN, Nieu NT, Ashton M. Artemisinin pharmacokinetics and efficacy in uncomplicated-malaria patients treated with two different dosage regimens. Antimicrob. Agents Chemother. 46, 1026-1031 (2002).
27. Gordi T, Lepist EI. Artemisinin derivatives: Toxic for laboratory animals, safe for humans? Toxicol. Lett. 147, 99-107 (2004).
28. Li Q, Xie LH, Si Y et al. Toxicokinetics and hydrolysis of artelinate and artesunate in malaria-infected rats. Int. J. Toxicol. 24, 241-250 (2005).
29. Titulaer HAC, Zuidema J, Kager PA et al. The pharmacokinetics of artemisinin after oral, intramuscular and rectal administration to volunteers. J. Pharm. Pharmacol. 42, 810-813 (1990).
30. Navaratnam V, Mansor SM, Sit NW et al. Pharmacokinetics of artemisinin-type compounds. Clin. Pharmacokinet. 39, 255-270 (2000).
31. Wongsrichanalai C, Wimonwattrawatee T, Sookto P et al. In vitro sensitivity of Plasmodium falciparum to artesunate in Thailand. Bull. WHO 77, 392-398 (1999).
32. Axerio-Cilies P, Casta-Neda IP, Mirza A, Reynisson J. Investigation of the incidence of 'undesirable' molecular moieties for high-throughput screening compound libraries in marketed drug compounds. Eur. J. Med. Chem. 44, 1128-1134 (2009).
33. Hartwig OH. Pharmacokinetic considerations of common analgesics and antipyretics. Am. J. Med. 75, 30-37 (1983).
34. Karbwang J, White NJ. Clinical pharmacokinetics of mefloquine. Clin. Pharmacokinet. 19, 264-279 (1990).
35. Dowling J, Isbister GK, Kirkpatrick CM, Naidoo D, Graudins A. Population pharmacokinetics of intravenous, intramuscular, and intranasal naloxone in human volunteers. Ther. Drug Monit. 30, 490-496 (2008).
36. Lamp KC, Bailey EM, Rybak MJ. Ofloxacin clinical pharmacokinetics. Clin. Pharmacokinet. 22, 32-46 (1992).
37. Ribera E, Azuaje C, Lopez RM et al. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. J. Antimicrob. Chemother. 59, 690-697 (2007).
38. Merry C, Barry MG, Mulcahy F et al. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 11, F29-F33 (1997).
39. Howden CW. Clinical pharmacology of omeprazole. Clin. Pharmacokinet. 20, 38-49 (1991).
40. Olbe L, Cederberg C, Lind T et al. Effect of omeprazole on gastric acid secretion and plasma gastrin. J. Gastroenterol. Hepatol. 4, 19-25 (1989).
41. Lalonde RL, Kowalski KG, Hutmacher MM et al. Model-based drug development. Clin. Pharmacol. Ther. 82, 21-32 (2007).
42. Atkinson AJ, Lalonde RL. Introduction of quantitative methods in pharmacology and clinical pharmacology: A historical overview. Clin. Pharmacol. Ther. 82, 3-6 (2007).